Our vision is to drastically reduce mortality caused by infectious diseases through increased use of affordable diagnostics.
Immuno-Mycologics, Inc. (IMMY) is a US-based organization that was founded in 1979 with a particular focus in mycology, or the study of fungi. Back then, mycology was virtually a forgotten area in the clinical laboratory, and there was a definite need for diagnostic products to detect fungal infections.
Over the last thirty years, IMMY has evolved from a company that filled a need in the market to an organization whose main focus is to save lives—period. We still devote a large amount of time to manufacturing high-quality fungal diagnostics, but our scope has broadened immensely.
Our most recent endeavors have centered on improving diagnostics for the developing world. Areas like sub-Saharan Africa lack the necessary infrastructure to provide patients with adequate healthcare.
However, we can help alleviate this problem by delivering diagnostics that can be performed without high-technology laboratory equipment or even electricity in general.
IMMY takes pride in producing reliable, accurate diagnostics, but above all we want to play a role in raising the standard of healthcare for patients all over the world.
IMMY in the news
Medical Laboratory Observer - March 2013.
"Sensitivity and specificity of a new cryptococcal antigen lateral flow assay in serum and cerebrospinal fluid"
SCACM - Cincinnati , OH
March 19 - 22, 2014
ASM - New York City
April 25, 2014
Latest IMMY Blog post